Genmab A/S (NASDAQ:GMAB) Downgraded to Hold Rating by Wall Street Zen

Genmab A/S (NASDAQ:GMAB - Get Free Report) was downgraded by Wall Street Zen from a "buy" rating to a "hold" rating in a research report issued on Friday.

A number of other research firms have also weighed in on GMAB. HC Wainwright reiterated a "buy" rating and issued a $37.00 price target (down previously from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. BNP Paribas raised Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 11th. Leerink Partnrs raised Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. Leerink Partners raised Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price target on the stock in a research note on Thursday, February 13th. Finally, Sanford C. Bernstein cut Genmab A/S from a "market perform" rating to an "underperform" rating in a research note on Tuesday, April 1st. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Genmab A/S presently has a consensus rating of "Moderate Buy" and a consensus target price of $39.17.

Genmab A/S Trading Up 1.8%

GMAB stock traded up $0.39 during trading hours on Friday, hitting $22.20. 956,446 shares of the stock traded hands, compared to its average volume of 1,156,026. The stock has a 50-day simple moving average of $20.14 and a 200 day simple moving average of $20.67. Genmab A/S has a one year low of $17.24 and a one year high of $28.56. The company has a market cap of $14.23 billion, a P/E ratio of 12.76, a P/E/G ratio of 2.65 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.08. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. The business had revenue of $715.00 million during the quarter, compared to analysts' expectations of $5.17 billion. Analysts forecast that Genmab A/S will post 1.45 earnings per share for the current year.

Institutional Investors Weigh In On Genmab A/S

A number of institutional investors have recently bought and sold shares of the business. Orbis Allan Gray Ltd boosted its position in Genmab A/S by 102.8% during the 1st quarter. Orbis Allan Gray Ltd now owns 5,710,741 shares of the company's stock worth $111,816,000 after acquiring an additional 2,895,179 shares during the period. Deep Track Capital LP acquired a new stake in Genmab A/S during the 4th quarter worth about $41,740,000. Renaissance Technologies LLC boosted its position in Genmab A/S by 7.8% during the 4th quarter. Renaissance Technologies LLC now owns 1,926,150 shares of the company's stock worth $40,199,000 after acquiring an additional 139,722 shares during the period. Brandywine Global Investment Management LLC boosted its position in Genmab A/S by 6.0% during the 1st quarter. Brandywine Global Investment Management LLC now owns 1,717,397 shares of the company's stock worth $33,627,000 after acquiring an additional 97,633 shares during the period. Finally, Two Sigma Investments LP boosted its position in Genmab A/S by 122.2% during the 4th quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company's stock worth $35,612,000 after acquiring an additional 938,455 shares during the period. 7.07% of the stock is currently owned by institutional investors and hedge funds.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.